{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/macular-degeneration-age-related/management/suspected-amd/","result":{"pageContext":{"chapter":{"id":"623a85d0-3eef-5b46-a5a6-0c14facafc46","slug":"suspected-amd","fullItemName":"Scenario: Suspected AMD","depth":2,"htmlHeader":"<!-- begin field 245f91a4-80e0-42dc-b3de-8a9def287206 --><h2>Scenario: Suspected age-related macular degeneration</h2><!-- end field 245f91a4-80e0-42dc-b3de-8a9def287206 -->","summary":"Covers the primary care management of people with suspected age-related macular degeneration.","htmlStringContent":"<!-- begin item d1aac64e-a97c-4e70-83e6-70f784ff2f02 --><!-- begin field 67cd5817-d683-43c4-89c6-acd900ab57e8 --><p>From age 50 years onwards.</p><!-- end field 67cd5817-d683-43c4-89c6-acd900ab57e8 --><!-- end item d1aac64e-a97c-4e70-83e6-70f784ff2f02 -->","topic":{"id":"bb3e11cb-517f-5331-9de9-039d796fed2d","topicId":"819a45d3-fd1c-42c7-8420-27d4daf53cc2","topicName":"Macular degeneration - age-related","slug":"macular-degeneration-age-related","lastRevised":"Last revised in October 2020","chapters":[{"id":"8dda5709-9896-57f9-9907-7fb9c46fe863","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"bb451071-7381-59cb-aa21-2b2bccafe2d2","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"5006d91f-871e-5987-a351-38613676d868","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"b46dda65-9a23-5d6c-9afe-03e05a87cc3c","slug":"changes","fullItemName":"Changes"},{"id":"a82ab674-261f-5a3d-8d12-5c13643cd924","slug":"update","fullItemName":"Update"}]},{"id":"e40fe343-86d1-5303-af86-c3b22d664113","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"807a5294-312b-51b7-8a2b-2b7d9c18a2a2","slug":"goals","fullItemName":"Goals"},{"id":"875cd1b7-ea38-5e4d-b1ac-1c4d4e110927","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"1c4bcbde-43f9-57c5-87d2-37e2a7bfc7b3","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"73e19abc-9ba2-505a-aae8-23b40e76c49f","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"cb9a7aab-681a-5b78-aca6-dcb97a9ae535","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"25a06a16-e897-5cb6-bdf2-99705c2c3f77","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"7cb3e392-3b5c-558a-988c-646bacf307bb","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"69a4bcc6-b18d-52c2-b7f8-b74b4bebf32c","slug":"definition","fullItemName":"Definition"},{"id":"e34a411a-f7c0-5084-965b-49ac89736d30","slug":"classification","fullItemName":"Classification"},{"id":"d537f969-c989-57cd-824a-d0718c657988","slug":"prevalence","fullItemName":"Prevalence"},{"id":"4098eb73-c982-50a6-830c-61d7dc25c997","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"c49a0066-054e-5666-9b2d-7bad39b079cc","slug":"prognosis","fullItemName":"Prognosis"},{"id":"1313d171-0d54-5814-baef-2c79e54a147e","slug":"complications","fullItemName":"Complications"}]},{"id":"5daaa827-5772-5a33-8675-cf20b916db2e","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"7fd2b2d6-9e86-5014-bc61-f30ce19d5712","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"fa4cdf98-731f-5fab-b1b9-802d0ad26a9e","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"491fb145-6067-5e5d-b364-2a3d874dcbde","fullItemName":"Management","slug":"management","subChapters":[{"id":"623a85d0-3eef-5b46-a5a6-0c14facafc46","slug":"suspected-amd","fullItemName":"Scenario: Suspected AMD"},{"id":"1d91de12-c8ef-5335-9359-81816456fb81","slug":"confirmed-amd","fullItemName":"Scenario: Confirmed AMD"}]},{"id":"0c6673ad-62d1-59a7-93a7-dc791491644d","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"81330a87-dcef-52cd-9707-efa0e22c0435","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"565ac27d-4e4d-5f6c-ba0a-bef0793f4f68","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"97a694f8-29e3-5e9b-9e46-68e52e2499d0","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"adea819b-f313-5842-8936-3b1d2feee7ad","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"e49d7e10-0bcd-5d89-b7f3-64d4ff858f1c","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"8059070a-a973-530d-8d9b-0e4cb14d5b65","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"4ea345d9-fe7e-558f-b710-2bb252185ef8","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"491fb145-6067-5e5d-b364-2a3d874dcbde","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"0a818cef-838a-56af-8af4-4b18b3630f81","slug":"primary-care-management","fullItemName":"Primary care management","depth":3,"htmlHeader":"<!-- begin field 1a827895-908d-4b25-9413-c84e78dfa797 --><h3>How should I manage a person with suspected age-related macular degeneration?</h3><!-- end field 1a827895-908d-4b25-9413-c84e78dfa797 -->","summary":null,"htmlStringContent":"<!-- begin item 2c997a1e-364c-40ef-b0e5-b1f4969d56d7 --><!-- begin field 5c7a462b-e326-46de-ad88-6345d801c2e8 --><ul><li><strong>If age-related macular degeneration (AMD) is suspected, refer the person urgently for ophthalmology assessment and investigations. </strong><ul><li>Ideally, the person should be seen within 1 week of referral. </li><li>Urgent referral is particularly important in people who present with visual distortion (metamorphopsia), or visual loss that is of rapid onset, as this may indicate neovascular AMD. </li><li>Refer to one of the following, the choice depending on local referral pathways: <ul><li>A fast-track macular or retina clinic (if available).</li><li>A local district general hospital eye service.</li><li>An appropriately trained optometrist — this is only an option if the person will be seen by the optometrist within 1 week, and the optometrist is able and willing to refer directly to an ophthalmologist if neovascular AMD is identified.</li></ul></li><li>Advise the person that if either there is a delay of more than 1 week in being seen by an optometrist or ophthalmologist, or symptoms become worse while they are waiting to be seen, then they should attend eye casualty, if available, as soon as possible, or seek other immediate medical attention to expedite urgent specialist assessment.</li></ul></li></ul><!-- end field 5c7a462b-e326-46de-ad88-6345d801c2e8 --><!-- end item 2c997a1e-364c-40ef-b0e5-b1f4969d56d7 -->","subChapters":[{"id":"4f8193f3-7d22-50fa-a9e0-14de5920eebc","slug":"secondary-care-investigations","fullItemName":"Secondary care investigations","depth":4,"htmlHeader":"<!-- begin field cf0d6c14-ad75-4146-aa81-11ddf320fe5a --><h4>What investigations are performed in secondary care to confirm the diagnosis?</h4><!-- end field cf0d6c14-ad75-4146-aa81-11ddf320fe5a -->","summary":null,"htmlStringContent":"<!-- begin item fcf901b1-abe7-41fa-a746-3cae702d26db --><!-- begin field 8276f142-3a1d-438e-bbc4-22b631b804b4 --><ul><li><strong>Slit-lamp biomicroscopy</strong> is used to identify drusen and pigmentary, exudative, haemorrhagic, or atrophic changes affecting the macula. It can also help to detect retinal thickening or elevation due to neovascular age-related macular degeneration (AMD). </li><li><strong>Colour fundus photography</strong> is used to provide a record of the appearance of the retina.</li><li><strong>Fluorescein angiography</strong> is used if neovascular AMD is suspected, in order to confirm the diagnosis and assess the type, extent, size, and location of lesions. Fluorescein dye is injected intravenously and photographs of the retina are taken serially to detect abnormal vasculature or leakage from capillaries. </li><li><strong>Indocyanine green angiography</strong> may be used to visualize the choroidal circulation that provides additional information to fluorescein angiography. It also involves intravenous injection of a dye. </li><li><strong>Optical coherence tomography</strong> is a non-invasive imaging investigation that is used to produce high-resolution cross-sectional and three-dimensional images of the retina (by analyzing wave patterns of reflected laser light).<ul><li>The Royal College of Ophthalmologists guideline states that this test is mandatory for diagnosis and monitoring response to therapy.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/macular-degeneration-age-related/references/\">Royal College of Ophthalmologists, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/macular-degeneration-age-related/references/\">BMJ, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/macular-degeneration-age-related/references/\">NICE, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/macular-degeneration-age-related/references/\">AAO, 2019</a>]</p><!-- end field 8276f142-3a1d-438e-bbc4-22b631b804b4 --><!-- end item fcf901b1-abe7-41fa-a746-3cae702d26db -->","subChapters":[]},{"id":"0cd0242b-a48c-5e3a-adac-83a13e3cd498","slug":"basis-for-recommendation-194","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 7963c902-dcc3-4f6a-a869-837ed6d36bd1 --><h4>Basis for recommendation</h4><!-- end field 7963c902-dcc3-4f6a-a869-837ed6d36bd1 -->","summary":null,"htmlStringContent":"<!-- begin item 1942400a-2dc2-4a0f-86a0-beb38ff8931f --><!-- begin field 61e417c8-c4d6-49ec-8b8d-e88dbb47af2b --><p>These recommendations are based on the Royal College of Ophthalmologists (RCO) <em>Guidelines for the management of age-related macular degeneration </em>(AMD) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/macular-degeneration-age-related/references/\">Royal College of Ophthalmologists, 2013</a>] and the American Association of Ophthalmology (AAO) guideline <em>Age-related macular degeneration preferred practice pattern</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/macular-degeneration-age-related/references/\">AAO, 2019</a>].</p><ul><li>The basis for referring urgently is that there are treatments available in secondary care that should be given as soon as possible after neovascular AMD is confirmed in order to prevent visual loss. <ul><li>Early detection of AMD and prompt treatment improves the visual outcome [<a class=\"bibliography-reference internal-reference\" href=\"/topics/macular-degeneration-age-related/references/\">AAO, 2019</a>].</li></ul></li><li>The statement that urgent referral is particularly important in people who present with distortion (metamorphopsia) or visual loss that is of rapid onset is based on the expert opinion of several previous external reviewers of this CKS topic who stated that such a history is highly suggestive of neovascular AMD. </li></ul><!-- end field 61e417c8-c4d6-49ec-8b8d-e88dbb47af2b --><!-- end item 1942400a-2dc2-4a0f-86a0-beb38ff8931f -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}